

Oracle Argus Safety

South Korea MFDS E2B(R3) Best Practices



Release 8.4
F51733-01
September 2022

ORACLE®

F51733-01

Copyright © 2020, 2022, Oracle and/or its affiliates.

This software and related documentation are provided under a license agreement containing restrictions on use and disclosure and are protected by intellectual property laws. Except as expressly permitted in your license agreement or allowed by law, you may not use, copy, reproduce, translate, broadcast, modify, license, transmit, distribute, exhibit, perform, publish, or display any part, in any form, or by any means. Reverse engineering, disassembly, or decompilation of this software, unless required by law for interoperability, is prohibited.

The information contained herein is subject to change without notice and is not warranted to be error-free. If you find any errors, please report them to us in writing.

If this is software, software documentation, data (as defined in the Federal Acquisition Regulation), or related documentation that is delivered to the U.S. Government or anyone licensing it on behalf of the U.S. Government, then the following notice is applicable:

U.S. GOVERNMENT END USERS: Oracle programs (including any operating system, integrated software, any programs embedded, installed, or activated on delivered hardware, and modifications of such programs) and Oracle computer documentation or other Oracle data delivered to or accessed by U.S. Government end users are "commercial computer software," "commercial computer software documentation," or "limited rights data" pursuant to the applicable Federal Acquisition Regulation and agency-specific supplemental regulations. As such, the use, reproduction, duplication, release, display, disclosure, modification, preparation of derivative works, and/or adaptation of i) Oracle programs (including any operating system, integrated software, any programs embedded, installed, or activated on delivered hardware, and modifications of such programs), ii) Oracle computer documentation and/or iii) other Oracle data, is subject to the rights and limitations specified in the license contained in the applicable contract. The terms governing the U.S. Government's use of Oracle cloud services are defined by the applicable contract for such services. No other rights are granted to the U.S. Government.

This software or hardware is developed for general use in a variety of information management applications. It is not developed or intended for use in any inherently dangerous applications, including applications that may create a risk of personal injury. If you use this software or hardware in dangerous applications, then you shall be responsible to take all appropriate fail-safe, backup, redundancy, and other measures to ensure its safe use. Oracle Corporation and its affiliates disclaim any liability for any damages caused by use of this software or hardware in dangerous applications.

Oracle®, Java, and MySQL are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Intel and Intel Inside are trademarks or registered trademarks of Intel Corporation. All SPARC trademarks are used under license and are trademarks or registered trademarks of SPARC International, Inc. AMD, Epyc, and the AMD logo are trademarks or registered trademarks of Advanced Micro Devices. UNIX is a registered trademark of The Open Group.

This software or hardware and documentation may provide access to or information about content, products, and services from third parties. Oracle Corporation and its affiliates are not responsible for and expressly disclaim all warranties of any kind with respect to third-party content, products, and services unless otherwise set forth in an applicable agreement between you and Oracle. Oracle Corporation and its affiliates will not be responsible for any loss, costs, or damages incurred due to your access to or use of third-party content, products, or services, except as set forth in an applicable agreement between you and Oracle.

Contents

	Preface	
	Documentation accessibility	v
	Diversity and Inclusion	v
	Related resources	v
	Access to Oracle Support	v
1	Revision history	
2	Introduction	
3	Reporting destinations setup	
4	Reporting rules setup	
5	Set up an E2B(R3) profile for ICSR and ACK	
6	MFDS codes for Products and Ingredients in Post-marketed Domestic Cases	
7	WHO codes for Products and Ingredients in Post-marketed Foreign Cases	
	Difference between B-format and C-format	7-1
	For Companies using WHO-DD C3 format	7-2
	For Companies using WHO-DD B3 format	7-5

- 8 Clinical Trial Approval Number (C.5.1.r.1) and Clinical Trial Serial Number (C.5.3) for Study cases

- 9 About the Study Name (C.5.2) for the Study cases

- 10 Other Health Professional Type (C.2.r.4.KR.1) for cases reported by Other Health Professional

- 11 Health Professional Type (C.3.1.KR.1) for cases with Health Professional Sender Type

- 12 Study Type (C.5.4.KR.1) for studies other than Clinical Trial or Compassionate Use studies

- 13 Regional Causality Assessment (G.k.9.i) for post-marketed Domestic cases and Study cases

- 14 Reporting to MFDS for legacy cases

Preface

This preface contains the following sections:

- [Documentation accessibility](#)
- [Diversity and Inclusion](#)
- [Related resources](#)
- [Access to Oracle Support](#)

Documentation accessibility

For information about Oracle's commitment to accessibility, visit the Oracle Accessibility Program website at <http://www.oracle.com/pls/topic/lookup?ctx=acc&id=docacc>.

Diversity and Inclusion

Oracle is fully committed to diversity and inclusion. Oracle respects and values having a diverse workforce that increases thought leadership and innovation. As part of our initiative to build a more inclusive culture that positively impacts our employees, customers, and partners, we are working to remove insensitive terms from our products and documentation. We are also mindful of the necessity to maintain compatibility with our customers' existing technologies and the need to ensure continuity of service as Oracle's offerings and industry standards evolve. Because of these technical constraints, our effort to remove insensitive terms is ongoing and will take time and external cooperation.

Related resources

For information about Oracle Argus patches, see [My Oracle Support](#).

All documentation and other supporting materials are available on the [Oracle Help Center](#).

Access to Oracle Support

To receive support assistance, determine whether your organization is a cloud or on-premises customer. If you're not sure, use Support Cloud.

Cloud customers receive support assistance through Support Cloud

Oracle customers that have purchased support have access to electronic support through Support Cloud.

Contact our Oracle Customer Support Services team by logging requests in one of the following locations:

- English interface of Oracle Health Sciences Customer Support Portal (<https://hsgbu.custhelp.com/>)
- Japanese interface of Oracle Health Sciences Customer Support Portal (<https://hsgbu-jp.custhelp.com/>)

You can also call our 24x7 help desk. For information, visit <http://www.oracle.com/us/support/contact/health-sciences-cloud-support/index.html> or visit <http://www.oracle.com/pls/topic/lookup?ctx=acc&id=trs> if you are hearing impaired.

On-premises customers receive support assistance through My Oracle Support

Oracle customers that have purchased support have access to electronic support through My Oracle Support. For information, visit <http://www.oracle.com/pls/topic/lookup?ctx=acc&id=info> or visit <http://www.oracle.com/pls/topic/lookup?ctx=acc&id=trs> if you are hearing impaired.

1


Revision history

Argus Version	Description
8.2.2	First release
8.2.3	<ul style="list-style-type: none">Added the "About the study name (C.5.2) for the Study cases" chapter.Added a note about WHODrug Link Korea in the "MFDS codes for Products and Ingredients in Post-marketed Domestic Cases" chapter.
8.2.3.1	Revised as per the business rules published on: <ul style="list-style-type: none">March 9, 2021March 16, 2021April 6, 2021May 27, 2021.
8.4	Revised as per the business rules published on: <ul style="list-style-type: none">August 4, 2021September 15, 2021 Revised as per the Implementation guide published on July 7, 2021.

2

Introduction

MFDS, the South Korean Health Authority, published the guidelines for Electronic Transmission of Individual Case Safety Reports E2B(R3) Data Elements and Message Specification [Specification for an Applicant] in January 2019. The revised versions of this guideline were published in November 2020 and in July 2021.



Oracle Argus Safety is enhanced to support out-of-the-box E2B(R3) profile to submit PMSR and CT cases to South Korean Health Authority MFDS (Ministry of Food and Drug Safety). Pharma companies must submit ICSRs in E2B(R3) format starting June 2021.

There are 14 Regional elements added to those specified in the ICH E2B(R3):

Element ID	Element description (English)	Element description (Korean)
C.2.r.4.KR.1	Other Health Professional Type	기타 의료전문가 구분
C.3.1.KR.1	Health Professional Type	의료 전문가 상세구분
C.5.4.KR.1	Other Studies Type	기타 시험 상세구분
D.8.r.1.KR.1a	Medicinal Product Version	의약품 코드 버전
D.8.r.1.KR.1b	Medicinal Product ID	의약품 코드

Element ID	Element description (English)	Element description (Korean)
D.10.8.r.1.KR.1a	Medicinal Product Version	의약품 코드 버전
D.10.8.r.1.KR.1b	Medicinal Product ID	의약품 코드
G.k.2.1.KR.1a	Medicinal Product Version	의약품 코드 버전
G.k.2.1.KR.1b	Medicinal Product ID	의약품 코드
G.k.2.3.r.1.KR.1a	Substance ID Version	성분 코드 버전
G.k.2.3.r.1.KR.1b	Substance ID	성분 코드
G.k.9.i.2.r.2.KR.1	MFDS Method of Assessment	평가 방법
G.k.9.i.2.r.3.KR.1	WHO-UMC Result of Assessment	WHO-UMC 평가 결과
G.k.9.i.2.r.3.KR.2	KRCT Result of Assessment	KRCT 평가 결과

This document lists the best practices and the recommendations for generating the MFDS E2B(R3) report from Oracle Argus Safety.

3

Reporting destinations setup

As per the Business rules for E2B(R3) published by MFDS

(약물이상반응 및 이상사례 개별 항목 검증 **틀.xlsx**), the reports have to be submitted to 4 different offices, based on the case data.

Therefore, BATCHMESSEAGERECEIVERIDENTIFIER [N.1.4] and MESSEAGERECEIVERIDENTIFIER [N.2.r.3] should have one of the below values:

- Domestic Clinical Trial: **MFDS-O-CT** (Test environment-MFDS-T-CT)
- Foreign Clinical Trial: **MFDS-O-CF** (Test environment-MFDS-T-CF)
- Compassionate Use: **MFDS-O-CU** (Test environment-MFDS-T-CU)
- Domestic Post-marketed: **MFDS-O-KR** (Test environment-MFDS-T-KR)
- Foreign Post-marketed: **MFDS-O-FR** (Test environment-MFDS-T-FR)

To achieve this, set up five different reporting destinations with agency identifiers in Oracle Argus Safety.

Agency Name	Agency Type	Department	Registration #	Contact Type
MFDS-O-CF	Regulatory Authority	MFDS Department for CF		
MFDS-O-CT	Regulatory Authority	MFDS Department for CT		
MFDS-O-CU	Regulatory Authority	MFDS Department for CU		
MFDS-O-FR	Regulatory Authority	MFDS Department for FR		
MFDS-O-KR	Regulatory Authority	MFDS Department for KR		

[Add New](#)

Modify Reporting Destination

Agency Information | Local Company Contact | **EDI** | SMTP

SGML XML Suppress Auto-scheduling

Agency Information

Agency Identifier: MFDS-O-KR | Identification Code: | Code Qualifier: |

Message Profile

ICH-ICSR V3.0 MESSAGE TEMPLATE - MFDS Mark as Auto Submit

ACK Profile

ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE - ICH | Submission date for ICSR's: |

Imported Case are assigned to: <site of importing user> | Initial Workflow State: | XML Source Classification: |

4

Reporting rules setup

Each report to MFDS has to be routed to CT/CU/KR/FR/CF Receiver Identifier depending on the case data such as Primary Reporter Country, Report Type, Observe Study Type.

You should set up the reporting rules with advanced conditions in Oracle Argus Safety.

Below are some sample reporting rules for understanding:

Country	License type	Agency	Rule name	Timeframe calendar days	Advanced condition
South Korea	Marketed Drug	MFDS-O-KR	Serious ADR Domestic	15	Primary Reporter Country = South Korea Report Type = Spontaneous
Germany	Marketed Drug	MFDS-O-FR	Serious ADR Foreign	15	Primary Reporter Country <> South Korea Report Type = Spontaneous
South Korea	Investigational Drug	MFDS-O-CT	Death/LT SUSAR	7	Primary Reporter Country = South Korea Report Type = Sponsored Trial Observe Study Type = Clinical Trial
South Korea	Investigational Drug	MFDS-O-CT	Serious Unexpected MFDS Clinical Trial rule	15	Primary Reporter Country = South Korea Report Type = Sponsored Trial Observe Study Type = Clinical Trial

Country	License type	Agency	Rule name	Timeframe calendar days	Advanced condition
Germany	Investigational Drug	MFDS-O-CF	Death/LT SUSAR	7	Primary Reporter Country <> South Korea Report Type = Sponsored Trial Observe Study Type = Clinical Trial
Germany	Investigational Drug	MFDS-O-CF	SUSAR MFDS Clinical Trial rule	15	Primary Reporter Country <> South Korea Report Type = Sponsored Trial Observe Study Type = Clinical Trial
South Korea	Investigational Drug	MFDS-O-CU	SUSAR MFDS Therapeutic Study rule	15	Primary Reporter Country = South Korea Report Type = Sponsored Trial Observe Study Type = Compassionate Use
European Union	Investigational Drug	MFDS-O-CU	SUSAR MFDS Therapeutic Study rule	15	Primary Reporter Country <> South Korea Report Type = Sponsored Trial Observe Study Type = Compassionate Use
South Korea	Marketed Drug	MFDS-O-KR	SADR domestic	15	Primary Reporter Country = South Korea Report Type = Sponsored Trial Observe Study Type = Other Studies

Country	License type	Agency	Rule name	Timeframe calendar days	Advanced condition
South Korea	Marketed Drug	MFDS-O-FR	SADR foreign	15	Primary Reporter Country <> South Korea Report Type = Sponsored Trial Observe Study Type = Other Studies

The following types of cases and criteria need to be met:

Cases	Criteria
KR case (Domestic Post Marketed)	<ul style="list-style-type: none"> cases that have REPORTTYPE [C.1.3] = 2, OBSERVESTUDYTYPE [C.5.4] = 3 and REPORTERCOUNTRYR3 [C.2.r.3] for Primary Reporter = KR cases that have REPORTTYPE [C.1.3] <> 2 and REPORTERCOUNTRYR3 [C.2.r.3] for Primary Reporter = KR
FR case (Foreign Post Marketed)	<ul style="list-style-type: none"> cases that have REPORTTYPE [C.1.3] = 2, OBSERVESTUDYTYPE [C.5.4] = 3 and REPORTERCOUNTRYR3 [C.2.r.3] for Primary Reporter <> KR cases that have REPORTTYPE [C.1.3] <> 2 and REPORTERCOUNTRYR3 [C.2.r.3] for Primary Reporter <> KR
CT case (Clinical Trial Domestic)	<ul style="list-style-type: none"> cases that have REPORTTYPE [C.1.3] = 2, OBSERVESTUDYTYPE [C.5.4] = 1 and REPORTERCOUNTRYR3 [C.2.r.3] for Primary Reporter = KR
CF case (Clinical Trial Foreign)	<ul style="list-style-type: none"> cases that have REPORTTYPE [C.1.3] = 2, OBSERVESTUDYTYPE [C.5.4] = 1 and REPORTERCOUNTRYR3 [C.2.r.3] for Primary Reporter <> KR
CU case (Compassionate Use)	<ul style="list-style-type: none"> cases that have REPORTTYPE [C.1.3] = 2 and OBSERVESTUDYTYPE [C.5.4] = 2

5

Set up an E2B(R3) profile for ICSR and ACK

To generate MFDS E2B(R3), set the **Message Profile** to **ICH-ICSR V3.0 MESSAGE TEMPLATE - MFDS** in the Modify Reporting Destination window.

To import MFDS ACK, set the **Message Profile** to **ICH-ICSR V3.0 MESSAGE TEMPLATE - MFDS** in the Modify Reporting Destination window.

The screenshot shows the 'Modify Reporting Destination' window with the 'EDI' tab selected. The 'Message Profile' dropdown menu is open, showing two options: 'ICH-ICSR V3.0 MESSAGE TEMPLATE - MFDS' and 'ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE - ICH'. A red box highlights these two options. Other fields in the window include 'Agency Identifier' (MFDS-O-KR), 'Identification Code', 'Code Qualifier', 'Mark as Auto Submit', 'Auto Accept ICSR's', 'Primary Receive Agency Selection Source Classification', 'MIR Report Format', 'Attachment Classification', and 'Allowed attachment file size (in MB)'.



Note:

The **ACK ICH-ICSR V3.0 ACKNOWLEDGEMENT TEMPLATE – ICH** profile is created using the new R3 framework, and is designed to be used with ICSR R3 profiles like MFDS.

6

MFDS codes for Products and Ingredients in Post-marketed Domestic Cases

MFDS has published a Regional Drug Dictionary with Product code and Ingredient code assigned for each Product and the set of Ingredients in that Product.

MFDS Product Code – 9-digit unique code per Product

MFDS Ingredient Code – 7-digit unique code per Ingredient

MFDS uploads the Drug Product License details spreadsheet in `nedrug.mfds.go.kr`, and this is refreshed in real time (on a daily basis). The location for file download is:

[Drug Product License details](#)

For post-marketed domestic cases, it is mandatory to transmit the MFDS Product code or MFDS Ingredient code for every Company and Non-company Product in the KR specific regional data elements (outlined in the table below) in E2B(R3) report as per the Business rules.

To achieve this, four new Case Form fields are introduced in Oracle Argus Safety.

It is required that companies manually enter the MFDS assigned Product code and Ingredient code in the Case Form fields as outlined in the table below.

Element ID	Element description	Case Form field
D.8.r.1.KR.1b	Medicinal Product ID (Patient Past drug Therapy)	Patient tab > Other Relevant History > MFDS Product Code
D.10.8.r.1.KR.1b	Medicinal Product ID (Parent Past drug Therapy)	Parent tab > Other Relevant History > MFDS Product Code
G.k.2.1.KR.1b	Medicinal Product ID (Suspect/Concomitant/Interacting Products)	Product tab > Product Information > MFDS Product Code
G.k.2.3.r.1.KR.1b	Substance ID (Ingredients of Suspect/Concomitant/Interacting Products)	Product tab > Substance Information > MFDS Ingredient Code

1. Patient/Parent tab > Other Relevant History > MFDS Product Code:

2. Product tab > Product Information > MFDS Product Code

Drug

Product Information

Product Name: [Select] [Encode] Suspect Concomitant Treatment

HH Prod 1 MKT

Generic Name: CADMIUM SULFIDE

Product Identifier Type: [] Product Identifier: [] Version: [] **MFDS Product Code** OTC Product

Company Drug Code: [] Obtain Drug Country: KOREA, REPUBLIC OF Drug Code: [] WHO Medicinal Product ID: []

Formulation: Capsule Drug Authorization Country: KOREA, REPUBLIC OF Market Authorization Holder: Oracle Authorization Type: []

Concentration: 500 Units: gram Interaction?: [] Contraindicated?: [] Drug Not Administered

3. Product tab > Substance Information > MFDS Ingredient Code

Drug

Formulation: Capsule Drug Authorization Country: UNITED STATES Market Authorization Holder: Oracle

Concentration: [] Units: [] Interaction?: [] Contraindicated?: []

UD Number 1: [] UD Number 2: []

Substance Information (1) Add Delete

#	Substance Name	Substance Term ID	Version	Strength	Unit	MFDS Ingredient Code
1.	PACLITAXEL	[]	[]	[]	[]	[]

Note:

The Oracle Argus Safety roadmap aims to enhance data entry and to provide a way to automatically populate MFDS Product Code and MFDS Ingredient Code when any Product is added to case.

- For company products, this requires association of MFDS-specific codes in **Console > Product > License Configuration**.
- For non-company products, this requires association of MFDS-specific codes in WHO drug dictionary tables. Based on the discussions with [WHO-UMC](#), it is understood that WHO-UMC is working with MFDS to provide this mapping between WHO drug/ingredient codes and MFDS specific codes.
- The official release date of the WHODrug Link Korea first version is March 1st, 2021. This release is compatible with the March 2021 WHODrug Global release.

7

WHO codes for Products and Ingredients in Post-marketed Foreign Cases

For post-marketed foreign cases, it is mandatory to transmit the WHO Medicinal Product ID for every Company and Non-company Product, and the WHO CAS Number for every Ingredient of the Product in the KR specific regional data elements (outlined in the table below) in the E2B(R3) report as per the Business rules.



Note:

Based on the discussion with MFDS, only WHO Global C3 coding is accepted while submitting foreign ICSRs. ICSRs using other formats (e.g. B3 format) will be rejected.

Element ID	Element description	Data to transmit
D.8.r.1.KR.1a	WHO-DD version	WHO-DD version
D.8.r.1.KR.1b	Medicinal Product ID (Patient Past drug Therapy)	WHO Medicinal Product ID
D.10.8.r.1.KR.1a	WHO-DD version	WHO-DD version
D.10.8.r.1.KR.1b	Medicinal Product ID (Parent Past drug Therapy)	WHO Medicinal Product ID
G.k.2.1.KR.1a	WHO-DD version	WHO-DD version
G.k.2.1.KR.1b	Medicinal Product ID (Suspect/Concomitant/Interacting Products)	WHO Medicinal Product ID
G.k.2.3.r.1.KR.1a	WHO-DD version	WHO-DD version
G.k.2.3.r.1.KR.1b	Substance ID (Ingredients of Suspect/Concomitant/Interacting Products)	WHO CAS Number

For more information, see:

- [Difference between B-format and C-format](#)
- [For Companies using WHO-DD C3 format](#)
- [For Companies using WHO-DD B3 format](#)

Difference between B-format and C-format

B-formats contain information about trade names, ingredients and ATC classification(s). The unique key is the alphanumeric **Drug Code**.

C-formats contain all the B-format information (including the Drug Code), but has additional information regarding the countries where the product is marketed, Marketing Authorization Holders, pharmaceutical forms and strengths. The unique key is the alphanumeric **Medicinal Product ID**.

WHO B3 coding in Oracle Argus Safety

Drug Coding (WHODRUG GLOBAL B3 March 1, 2019)

Product Type ATC Code Drug Code Medicinal Prod ID Trade Name Ingredient Formulation Country Full Search

(All) Crocin

Trade Name	Formulation / Strength	Sales Country	Generic?
CROCIN			Y
CROCIN COLD N FLU			N
CROCIN COLD N FLU			N
CROCIN COLD N FLU			N
CROCIN COLD N FLU			N
CROCIN PAIN RELIEF			N
CROCIN [PARACETAMOL]			N
CROCIN:HYALURONIC ACID:PHOSPHOLIPIDS			Y
CROCINON			N

Drug Detail

Trade Name: CROCIN

MAH:

Drug Code: 144652.01.001 ATC Code: S01XA ATC Description: OTHER OPHTHALMOLOGICALS

Medicinal Product ID:

Ingredients: CROCIN

WHO C3 coding in Oracle Argus Safety

Drug Coding (WHO DDE C3 December 1, 2017)

Product Type ATC Code Drug Code Medicinal Prod ID Trade Name Ingredient Formulation Country Full Search

(All) Crocin

Trade Name	Formulation / Strength	Sales Country	Generic?
Crocin	Unspecified/Unspecified	PHL	N
Crocin	Unspecified/Unspecified	IND	N
Crocin	LIQUIDS, DROPS/Unspecified	IND	N
Crocin	Unspecified/Unspecified	IND	N
Crocin	LIQUIDS, SUSPENSIONS/Unspecified	IND	N
Crocin	LIQUIDS, SYRUPS/Unspecified	IND	N
Crocin	TABLETS/Unspecified	IND	N
Crocin	LIQUIDS, SYRUPS/Unspecified	PHL	N
Crocin	Unspecified/Unspecified	PHL	N
Crocin	TABLETS/Unspecified	PHL	N
Crocin	LIQUIDS, SUSPENSIONS/Unspecified	PHL	N
Crocin	Unspecified/Unspecified	UNS	N
Crocin cold n flu	Unspecified/Unspecified	IND	N
Crocin cold n flu	Unspecified/Unspecified	IND	N
Crocin cold n flu	Unspecified/Unspecified	UNS	N
Crocin cold n flu	COATED TABLETS, FILM/Unspecified	IND	N
Crocin cold n flu	COATED TABLETS, FILM/25 mg/5 mg/500 mg	IND	N
Crocin Cold n Flu	Unspecified/Unspecified	IND	N

Drug Detail

Trade Name: Crocin

MAH: Not specified

Drug Code: 000200.01.172 ATC Code: N02BE ATC Description: Anilides

Medicinal Product ID: 1440155

Ingredients: Paracetamol


For Companies using WHO-DD C3 format

For drugs autoencoding during case processing with WHO-DD C3 format, the dictionary is set in **Argus Console > System Configuration > System Management (Common Profile Switches) > Case Form Configuration > Auto Encoding** section.

Set the same WHO-DD C3 dictionary in the newly introduced Common Profile Switch in **Console > Common Profile Switch > E2B > Regional Drugs Dictionary**.

Note:

This switch will have no impact on case processing and it is used only for MFDS E2B(R3) reporting.



WHO Medicinal Product ID and WHO CAS Number are captured and transmitted as outlined in the table below.

For details, refer to the Business Rules defined in the E2B(R3) export mapping document.

Element ID	Element description	Data capture and transmitted from
D.8.r.1.KR.1a	WHO-DD version	Console > Common Profile Switch > E2B > Regional Drugs Dictionary
D.8.r.1.KR.1b	Medicinal Product ID (Patient Past drug Therapy)	Case Form > Patient > Other Relevant History > WHO Medicinal Product ID
D.10.8.r.1.KR.1a	WHO-DD version	Console > Common Profile Switch > E2B > Regional Drugs Dictionary
D.10.8.r.1.KR.1b	Medicinal Product ID (Parent Past drug Therapy)	Case Form > Parent > Other Relevant History > WHO Medicinal Product ID
G.k.2.1.KR.1a	WHO-DD version	Console > Common Profile Switch > E2B > Regional Drugs Dictionary
G.k.2.1.KR.1b	Medicinal Product ID (Suspect/Concomitant/Interacting Products)	Case Form > Product > WHO Medicinal Product ID
G.k.2.3.r.1.KR.1a	WHO-DD version	Console > Common Profile Switch > E2B > Regional Drugs Dictionary

Element ID	Element description	Data capture and transmitted from
G.k.2.3.r.1.KR.1b	Substance ID (Ingredients of Suspect/ Concomitant/Interacting Products)	WHO CAS Number is retrieved from WHO-DD C3 dictionary WHO_DRUG_C_SUBSTANCE table using Case Form > Product > Substance Information > Substance Name

For WHO drugs

To facilitate the capture of WHO Medicinal Product ID for Historical drugs, 2 Case Form fields are newly introduced, namely:

- **Case Form > Patient > Other Relevant History > WHO Medicinal Product ID**
- **Case Form > Parent > Other Relevant History > WHO Medicinal Product ID**

When drugs are coded during case processing with the WHO-DD C3 format, the WHO Medicinal Product ID is automatically populated from the WHO Drug browser.

For Company drugs

In Oracle Argus Safety Console, set the WHO Drug Code for company products. This will store the WHO Drug Code in LM_PRODUCT.DRL_ID and also the corresponding Medical Product ID in LM_PRODUCTS.MEDICINAL_PROD_ID.

When this Product is added in the case, the WHO Medicinal Product ID would be populated in **Case Form > Product**.

The screenshot displays the 'Drug Detail' window for 'Starzoko'. The 'Key Ingredients' section shows 'SIMVASTATIN'. The 'Dosage Formulation' is 'Tablet'. The 'Drug Detail' section includes 'Trade Name: Starzoko', 'MAH: Lupin', 'Drug Code: 008481.01.883', 'ATC Code: C10AA', 'ATC Description: HMG CoA reductase inhibitors', and 'Medicinal Product ID: 4016253'. The 'Ingredients' section lists 'Simvastatin'. The 'WHO Drug Code' field is highlighted with a red box, showing the value '008481.01.883'. The 'Medicinal Product ID' field is also highlighted with a red box, showing the value '4016253'.

The screenshot displays the 'Product Information' window for 'Starzoko KR'. The 'Product Identifier' section includes 'Company Drug Code', 'Obtain Drug Country: KOREA, REPUBLIC OF', 'Drug Code: 008481.01.883', and 'WHO Medicinal Product ID: 4016253'. The 'Formulation' section includes 'Tablet', 'Drug Authorization Country: KOREA, REPUBLIC OF', 'Market Authorization Holder: Drug and Devices Inc.', and 'Authorization Type'. The 'Drug Code' and 'WHO Medicinal Product ID' fields are highlighted with red boxes.

 **Note:**

During the E2B(R2/R3) import, the WHO Medicinal Product ID will be populated if the incoming XML contains a WHO Drug product that has a single match with the WHO Drug dictionary. This is applicable for WHO Medicinal Product ID on the Products tab, on the Patient tab > Other Relevant History section and on the Parent tab > Other Relevant History section.

For Companies using WHO-DD B3 format

For drugs auto encoding during case processing with WHO-DD B3 format, the dictionary is set in **Argus Console > System Configuration > System Management (Common Profile Switches) > Case Form Configuration > Auto Encoding** section.

For MFDS E2B(R3) reporting, since it is mandatory to send the WHO Medicinal Product ID and the WHO CAS Number from C3 format, it is recommended to load the WHO-DD C3 dictionary into Oracle Argus Safety. Technically, Oracle Argus Safety supports loading multiple WHO dictionary versions and formats.

Set the WHO-DD C3 dictionary in the newly introduced Common Profile Switch in **Console > Common Profile Switch > E2B > Regional Drugs Dictionary**.


 **Note:**

This switch shall not impact the Case processing and is used only for MFDS E2B(R3) reporting. Hence, companies can continue to code drugs with the WHO-DD B3 format as usual.

MFDS E2B(R3) mapping logic is designed to automatically fetch the WHO Medicinal Product ID and the WHO CAS Number from the C3 dictionary set in the Regional Drugs Dictionary based on the WHO Drug Code in the Oracle Argus Safety Case Form.

This mapping is designed in discussion with WHO-UMC to fetch the match from C3 where Country = Unspecified, MAH = Unspecified, Formulation = Unspecified, Strength = Unspecified.

For example, for the ABAPEN drug coded using B3 format, Oracle Argus Safety mapping logic fetches the corresponding C3 format data, as in the image below:



Note:

WHO-UMC does not provide official mapping between B format and C format. Oracle discussed this challenge with WHO-UMC, and they acknowledge the challenge. WHO-UMC are currently engaging with MFDS with the ultimate aim to create mappings between WHODrug B3 and WHODrug C3 format.

Until official mapping between B format and C format is provided, it is recommended to use out-of-the-box MFDS E2B(R3) mapping logic in Oracle Argus Safety.

Note:

The customization of B3 to C3 mapping can be achieved by the customizing export mapping query for the below elements in **Console > Interchange Mapping > MFDS profile**:

- PATIENTPASTDRUGTHERAPY
- PARENTPASTDRUGTHERAPY
- DRUG
- ACTIVESUBSTANCE

The `pkg_mfds.sql` file is unwrapped for this purpose.

WHO Medicinal Product ID and WHO CAS Number are captured and transmitted as outlined in the table below.

For details, refer to the Business Rules defined in E2B(R3) export mapping document.

Element ID	Element description	Data capture and transmitted from
D.8.r.1.KR.1a	WHO-DD version	Console > Common Profile Switch > E2B > Regional Drugs Dictionary
D.8.r.1.KR.1b	Medicinal Product ID (Patient Past drug Therapy)	WHO Medicinal Product ID is retrieved from WHO-DD C3 dictionary WHO_DRUG_C_MASTER table using Drug code of the Patient past drug details
D.10.8.r.1.KR.1a	WHO-DD version	Console > Common Profile Switch > E2B > Regional Drugs Dictionary
D.10.8.r.1.KR.1b	Medicinal Product ID (Parent Past drug Therapy)	WHO Medicinal Product ID is retrieved from WHO-DD C3 dictionary WHO_DRUG_C_MASTER table using Drug code of the Parent past drug details
G.k.2.1.KR.1a	WHO-DD version	Console > Common Profile Switch > E2B > Regional Drugs Dictionary
G.k.2.1.KR.1b	Medicinal Product ID (Suspect/Concomitant/Interacting Products)	WHO Medicinal Product ID is retrieved from WHO-DD C3 dictionary WHO_DRUG_C_MASTER table using Case Form > Product > Drug Code
G.k.2.3.r.1.KR.1a	WHO-DD version	Console > Common Profile Switch > E2B > Regional Drugs Dictionary
G.k.2.3.r.1.KR.1b	Substance ID (Ingredients of Suspect/Concomitant/Interacting Products)	WHO CAS Number is retrieved from WHO-DD C3 dictionary WHO_DRUG_C_SUBSTANCE table using Case Form > Product > Substance Information > Substance Name

8


Clinical Trial Approval Number (C.5.1.r.1) and Clinical Trial Serial Number (C.5.3) for Study cases

For cases that are Clinical Trial (CT) or Compassionate Use (CU), it is mandatory to transmit the data as outlined in the table below.

Element ID	Element description	Data to transmit
C.5.1.r.1	Study Registration Number	Clinical Trial Approval Number issued by MFDS
C.5.3	Sponsor Study Number	Clinical Trial Serial Number or Clinical Trial Plan Number issued by MFDS

To achieve this, set up the MFDS specific numbers in **Console > Study Configuration > Clinical References** section:

- To transmit Clinical Trial Approval Number issued by MFDS in C.5.1.r.1, select **Reference Type = CT Approval Number**, and enter the Reference Number for Country = Korea, Republic of.
- To transmit Clinical Trial Serial Number issued by MFDS in C.5.3, select **Reference Type = CT Serial Number**, and enter the Reference Number for Country = Korea, Republic of.
- To transmit Clinical Trial Plan Number issued by MFDS in C.5.3, select **Reference Type = CT Plan Number** and enter the Reference Number for Country = Korea, Republic of.




The screenshot shows a table titled "Clinical References (2)" with columns for Reference Type, Country, and Reference Number. There are two rows of data:

Reference Type	Country	Reference Number
CT Approval Number	KOREA, REPUBLIC OF	MFDS001
CT Serial Number	KOREA, REPUBLIC OF	MFDS002

9

About the Study Name (C.5.2) for the Study cases

For the studies that need to be reported to MFDS, the study name should be configured to Korean language in **Argus Console > Business Configuration > Studies > Studies Configuration > Study Description**. If the configured data are available in Korean language, the same information is transmitted in STUDYNAME [C.5.2]. Otherwise, the configured data are transmitted in English language.



10

Other Health Professional Type (C.2.r.4.KR.1) for cases reported by Other Health Professional

Whenever a case is reported by Other Health Professional, **Case Form > General > Reporter Information > Reporter Type** is selected as **Other Health Professional**.

This transmits QUALIFICATIONR3 [C.2.r.4] = 3 (Other health professional), it is mandatory to transmit OTHERHEALTHPROFESSIONALS [C.2.r.4.KR.1].

Element ID	Element description	Allowed values
C.2.r.4.KR.1	Other Health Professional Type	1=Nurse 2=Other

To achieve this, Oracle Argus Safety Flexible code list is enhanced with additional values in **Console > Code Lists > Flexible re-categorization > REPORTER_TYPE**:

- The new MFDS attribute is added.
- The existing E2B(R3) attribute is updated for the additional values.

If a case is reported by a Nurse, then select **Case Form > General > Reporter Information > Reporter Type = Nurse**. MFDS E2B(R3) will transmit C.2.r.4 = 3 Other health professional and C.2.r.4.KR.1 = 1 Nurse.

If a case is reported by any other Health Professional, then select **Case Form > General > Reporter Information > Reporter Type = Other or Hospital**. MFDS E2B(R3) will transmit C.2.r.4 = 3 Other health professional and C.2.r.4.KR.1 = 2 Other.

What this means to business users: No additional data entry required (and derived from configuration).

English description	E2B	Ja	MFDS
Physician	1	医薬情報担当者	-
Company Representative	5	企業代表者	-
Other Health Professional	3	その他の医療専門家 ²	
Non-Health Professional	5	消費者またはその他の非医療専門家	
Nurse	3	看護師	1
Pharmacist	2	薬剤師	-
Consumer	5	消費者	-

English description	E2B	Ja	MFDS
Lawyer	4	弁護士	-
Other	5	その他	-
Professor	5	教授	-
Hospital	3	病院	2
Specialist	1	専門家	-

Health Professional Type (C.3.1.KR.1) for cases with Health Professional Sender Type

Whenever Sender Type is Health Professional with C.3.1 = 3 (Health professional) as set in the **Console > Reporting Destination > Local Company Contact > Sender Type**, it is mandatory to transmit HEALTHPROFESSIONALTYPE [C.3.1.KR.1].

Element ID	Element description	Allowed Values
C.3.1.KR.1	Health Professional Type	1=Clinic/Hospital 2=Pharmacy 3=Public Health Centre 4=Other

To achieve this, Oracle Argus Safety Flexible code list is enhanced with additional values in **Console > Code Lists > Flexible re-categorization > REPORTING_DESTINATION_TYPE**:

- The new MFDS attribute is added.
- The existing E2B(R3) attribute is updated for the additional values.

It is recommended to set the **Console > Reporting Destination > Local Company Contact > Sender Type** according to the Sender Type, so that C.3.1 will be transmitted as 3 (Health professional) and C.3.1.KR.1 will be transmitted as corresponding MFDS attribute value.

What this means to business users: No additional data entry required (and derived from configuration).

CODE	En	Ja	E2B_R3	MFDS
1	Pharmaceutical Company	製薬企業	1	-
2	Regulatory Authority	規制当局	2	-
3	Health Professional	医療専門家	3	4

CODE	En	Ja	E2B_R3	MFDS
4	Regional Pharmacovigilance Center	地域薬剤監視センター		-
5	WHO Collaboration Center for International Drug Monitoring	WHO 国際医薬品モニタリングセンター		-
6	Other	その他	6	-
7	Patient / Consumer	患者 / 消費者	7	-
8	Health Professional (Clinic/Hospital)	医療専門家(診療所/病院)	8	1
9	Health Professional (Pharmacy)	医療専門家(薬局)	9	2
10	Health Professional (Public Health Center)	医療専門家(保健所)	10	3
11	Health Professional (Other)	医療専門家(その他)	11	4

12

Study Type (C.5.4.KR.1) for studies other than Clinical Trial or Compassionate Use studies

It is mandatory to transmit OTHERSTUDIESTYPE [C.5.4.KR.1] when C.5.4 = 3 Other Studies.

Element ID	Element description	Allowed values
C.5.4.KR.1	Other Studies Type	1 = Investigation into usage when reporting for a review 2 = Post-marketing clinical study when reporting for a review 3 = Special investigation when reporting for a review 4 = Other

To achieve this, Oracle Argus Safety Flexible code list is enhanced with additional values in **Console > Code Lists > Flexible re-categorization > CASE_CLASSIFICATION:**

- The new MFDS attribute is added.
- The existing E2B(R3) attribute is updated for the additional values.

It is recommended to set the **Console > Business configuration > Studies > Observe Study Type** according to the Other Study Type so that C.5.4 will be transmitted as 3 (Other studies) and C.5.4.KR.1 will be transmitted as corresponding MFDS attribute value.

What this means to business users: No additional data entry required (and derived from configuration)

CODE	En	E2B	Ja	MFDS
1	Clinical Trial	1	臨床試験	-
2	Individual Patient Use	2	患者個人使用	-
3	Other Studies	3	その他の試験	4
4	CIRM Case	-	CIRM 症例	-
5	SAW not applicable to device	-	SAW (機器は非該当)	-
6	SAE not applicable to drug	-	SAE (薬品は非該当)	-
7	Combination Product	-	組合せ製品	-

CODE	En	E2B	Ja	MFDS
8	Investigation into usage	3	使用量の調査	1
9	Post-marketing clinical study	3	製造販売後治験チェック	
10	Special investigation	3	特別調査	3

13

Regional Causality Assessment (G.k.9.i) for post-marketed Domestic cases and Study cases

There are 3 regional KR elements described for Regional Causality Assessment.

For CT or CU cases, it is mandatory to transmit KRMETHODOFASSESSMENT [G.k.9.i.2.r.2.KR.1] and KRCTRESULTOFASSESSMENT [G.k.9.i.2.r.3.KR.2].

For Post-marketed Domestic cases, preference is given to Regional causality elements over ICH standard causality elements: KRMETHODOFASSESSMENT [G.k.9.i.2.r.2.KR.1] and WHOUMCRESLTOFASSESSMENT [G.k.9.i.2.r.3.KR.1].

Element ID	Element description	Allowed Values
G.k.9.i.2.r.2.KR.1	MFDS Method of Assessment	1=WHO-UMC 2=KRCT
G.k.9.i.2.r.3.KR.1	WHO-UMC Result of Assessment	1 = Certain 2 = Probable 3 = Possible 4 = Unlikely 5 = Conditional/unclassified 6 = Unassessable/unclassifiable nullFlavor: NA
G.k.9.i.2.r.3.KR.2	KRCT Result of Assessment	1 = Related 2 = Unrelated

To achieve this, Oracle Argus Safety Flexible code list is enhanced with additional values in **Console > Code Lists > Flexible re-categorization > CAUSALITY_CATEGORY**:

- The new MFDS attribute is added.
- The existing E2B(R3) attribute is updated for the additional values.

When a Medical Reviewer assesses **Case Form > Event > Event Assessment > Causality as Reported Result** and **Causality as Determined Result**, the MFDS specific codes are populated by out-of-the-box mapping logic in Regional Causality Assessment elements.



Note:

For Null flavor [NA], configure a flex code list with MFDS code as [NA]. This is not provided out-of-the-box.

Flexible Re-Categorization Code Lists				
Code List Name				
CAUSALITY_CATEGORY				
CAUSALITY_CATEGORY - CAUSALITY_CATEGORY				
en	REPORTABILITY	Ja	EU_CODE	MFDS
Almost Certain	1	ほぼ確実に ¹ 関連あり	1	1
Not Applicable	0		2	[NA]
Probable	1	おそらく ¹ 関連あり	1	2
Possible	1	関連があるかもしれ ¹ ない	1	3
Unlikely	0	関連はありそ ¹ ろくない	2	4
Not Related	0	関連なし	2	4
Unknown	1	不明	1	5
Not Reported	1	未報告	1	6
None	0	なし	2	6

For details, refer to the Business Rules defined in the E2B(R3) export mapping document.

What this means to business users: No additional data entry required (and derived from existing Causality Result).

CODE	En	REPORTABILITY	Ja	EU_CODE	MFDS
1	Almost Certain	1	ほぼ確実に ¹ 関連あり	1	1
2	Probable	1	おそらく ¹ 関連あり	1	2
3	Possible	1	関連があるかもしれ ¹ ない	1	3
4	Unlikely	0	関連はありそ ¹ ろくない	2	4
5	Not Related	0	関連なし	2	4
6	Unknown	1	不明	1	5
7	Not Reported	1	未報告	1	6
8	None	0	なし	2	6

14

Reporting to MFDS for legacy cases

No upgrade scripts are provided for reporting legacy cases to MFDS in E2B(R3) format. It is recommended to review the case data and ensure data is updated to satisfy the MFDS business rules.